[1]徐晓,梁景耀,叶瑞贤,等.沙利度胺辅助治疗新型冠状病毒(COVID-19)感染者的循证医学思考与可行性探索[J].中国皮肤性病学杂志,2020,(06):611-616.[doi:10.13735/j.cjdv.1001-7089.202002104]
 XU Xiao,LIANG Jingyao,YE Ruixian,et al.Feasibility of Adjuvant Therapy with Thalidomide in the Treatment of Patients Infected with Novel Coronavirus(COVID-19)According to Evidence-Based Medicine[J].The Chinese Journal of Dermatovenereology,2020,(06):611-616.[doi:10.13735/j.cjdv.1001-7089.202002104]
点击复制

沙利度胺辅助治疗新型冠状病毒(COVID-19)感染者的循证医学思考与可行性探索
分享到:

《中国皮肤性病学杂志》[ISSN:1001-7089/CN:61-1197/R]

卷:
期数:
2020年06期
页码:
611-616
栏目:
新冠专栏
出版日期:
2020-06-01

文章信息/Info

Title:
Feasibility of Adjuvant Therapy with Thalidomide in the Treatment of Patients Infected with Novel Coronavirus(COVID-19)According to Evidence-Based Medicine
文章编号:
1001-7089(2020)06-0611-06
作者:
徐晓12梁景耀12叶瑞贤12郑捷3张锡宝12
1.广州医科大学皮肤病研究所,广东 广州 510095; 2.广州市皮肤病防治所,广东 广州 510095; 3.上海交通大学瑞金医院皮肤科,上海 200025
Author(s):
XU Xiao12LIANG Jingyao12YE Ruixian12ZHENG Jie3ZHANG Xibao12
(1.Institute of Dermatology,Guangzhou Medical University,Guangzhou 510095,China; 2.Department of Dermatology,Guangzhou Institute of Dermatology,Guangzhou 510095,China; 3.Department of Dermatology,Ruijing Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 200025,China)
关键词:
新型冠状病毒 沙利度胺 疗效 循证医学
Keywords:
COVID-19 Thalidomide Efficacy Evidence-based medicine
分类号:
R 563.1
DOI:
10.13735/j.cjdv.1001-7089.202002104
文献标志码:
A
摘要:
新型冠状病毒(COVID-19)的发现以及其快速传播是对全国甚至全球公共卫生的挑战。如何有效控制传播,快速治愈感染者已经成为目前国家乃至全世界的抗疫焦点。目前对于新型冠状病毒感染的肺炎尚无明确有效的抗病毒药物,对患者均采用一般对症支持治疗,对于危及生命的重症肺炎患者使用糖皮质激素存在争议,临床急需更为有效的治疗药物。沙利度胺具有抗炎、抗纤维化、抗血管新生、免疫调节等多种作用,而无“免疫抑制剂”的副作用,在临床应用于上呼吸道感染所致的肺炎、肺损伤及肺纤维化等疾病的治疗,有效且安全。基于现有关于沙利度胺的基础研究和循证医学经验,探索沙利度胺辅助治疗新型冠状病毒重度感染者的肺炎及相关肺损伤,可为COVID-19重症感染者的治疗提供新的诊疗思路。
Abstract:
The emergence of novel coronavirus 2019(COVID-19)and its rapid spread poses critical challenges to public health in China and in the world.How to effectively control the spread and quickly cure the infection has become the focus.Currently,there is no definite effective antiviral drug for pneumonia caused by COVID-19 infection.Patients are treated with general support and symptomatic therapy,however,the application of glucocorticoids in life-threatening severe pneumonia is still controversial.Thus,more effective clinical drugs are urgently needed.Thalidomide has been widely used in the treatment of pneumonia caused by upper respiratory tract infection,lung injury and pulmonary fibrosis for its anti-inflammatory,anti-fibrotic,anti-angiogenesis,immunomodulation effects with good safety but with no side effects of “immunosuppressant”.Therefore,the exploration of adjuvant therapy with thalidomide in the treatment of novel coronavirus infection based on the preclinical research available and clinical experience from evidence-based medicine can provide new treatment avenues for the those severe cases with COVID-19 infection.

参考文献/References:

[1] 国家卫生健康委办公厅,国家中医药管理办公室.关于印发新型冠状病毒感染的肺炎诊疗方案(试行第五版修正版)的通知:国卫办医函〔2020〕117号[EB/OL].[2020-02-15].http://www.gov.cn/zhengce/zhengceku/2020-02/05/content_5474791.htm.
[2] Guan W,Ni Z,Hu Y,et al.Clinical characteristics of 2019 novel coronavirus infection in China[J].Med Rxiv,2020.02.06.20020974.
[3] Russell CD,Millar JE,Baillie JK.Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury[J].Lancet,2020,395(10223):473-475.
[4] Arabi YM,Mandourah Y,Al-Hameed F,et al.Corticosteroid therapy for critically ill patients with middle east respiratory syndrome[J].Am J Respir Crit Care Med,2018,197(6):757-767.
[5] Ni YN,Chen G,Sun J,et al.The effect of corticosteroids on mortality of patients with influenza pneumonia:a systematic review and meta-analysis[J].Crit Care,2019,23(1):99.
[6] Huang CL,Wang YM,Li XW,et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan,China[J].Lancet,2020,395(10223):497-506.
[7] Chen NS,Zhou M,Dong X,et al.Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan,China:a descriptive study[J].Lancet,2020,395(10223):507-513.
[8] McGee S,Hirschmann J.Use of corticosteroids in treatinginfectious diseases[J].Arch Intern Med,2008,168(10):1034-1046.
[9] Ashbaugh DG,Bigelow DB,Petty TL,et al.Acute respiratory distress in adults[J].Lancet,1967,2(7511):319-323.
[10] 赵海燕,王雨平,单可记.重症甲型H1N1流感患者临床救治回顾分析[J].中国现代医药杂志,2010,12(4):40-43.
[11] 杨渭临,章琳,张王刚,等.沙利度胺治疗老年肺间质纤维化38例分析[J].陕西医学杂志,2011,40(1):93-95.
[12] 石宗民,阳永珍,李庆,等.沙利度胺联合强的松治疗老年肺间质纤维化的疗效观察[J].中国医药指南,2017,15(8):115.
[13] 张佳红,周淑红,周静,等.沙利度胺治疗结缔组织病相关肺间质疾病的临床观察[J].临床荟萃,2019,34(7):622-625.
[14] 李艳萍.沙利度胺在百草枯中毒肺纤维化的疗效分析[J].航空航天医学杂志,2017,28(12):1497-1498.
[15] Ruemmele FM,Veres G,Kolho KL,et al.Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease[J].J Crohns Colitis,2014,8(10):1179-1207.
[16] 中华医学会儿科学分会消化学组,中华医学会儿科学分会临床营养学组.儿童炎症性肠病诊断和治疗专家共识[J].中华儿科杂志,2019,57(7):501-507.
[17] 中国中枢神经系统胶质瘤诊断和治疗指南编写组.中国中枢神经系统胶质瘤诊断与治疗指南(2015)[J].中华医学杂志,2016,96(7):485-509.
[18] 广东省地中海贫血防治协会.儿童非输血依赖型地中海贫血的诊治和管理专家共识[J].中国实用儿科杂志,2018,33(12):6-11.
[19] 刘黎黎,姜毅,侯新琳,等.4月龄以内起病的炎症性肠病7例临床特点及基因诊断病例系列报告[J].中国循证儿科杂志,2016,11(4):285-289.
[20] Richardson P,Anderson K.Immunomodulatory analogs of thalidomide:an emerging new therapy in myeloma[J].J Clin Oncol,2004,22(16):3212-3214.
[21] Liu T,Guo F,Zhu X,et al.Thalidomide and its analogues:A review of the potential for immunomodulation of fibrosis diseases and opthalmopathy[J].Exp Ther Med,2017,14(6):5251-5257.
[22] Stewart AK.Medicine.How thalidomide works against cancer[J].Science,2014,343(6168):256-257.
[23] Zhu H,Shi X,Ju D,et al.Anti-inflammatory effect of thalidomide on H1N1 influenza virus-induced pulmonary injury in mice[J].Inflammation,2014,37(6):2091-2098.
[24] Bartlett JB,Dredge K,Dalgleish AG.The evolution of thalidomide and its IMiD derivatives as anticancer agents[J].Nat Rev Cancer,2004,4(4):314-322.
[25] Riches JC,Gribben JG.Immunomodulation and immune reconstitution in chronic lymphocytic leukemia[J].Semin Hematol,2014,51(3):228-234.
[26] Stephen K,Viraj B,Angelina J,et al.Clinical perspectives into the use of thalidomide for central nervous system tuberculosis[J].Eur J Neurol,2018,25(11):1345-1351.
[27] Zhao L,Xiao K,Wang H,et al.Thalidomide has a therapeutic effect on interstitial lung fibrosis:Evidence from in vitro and in vivo studies[J].Clin Exp Immunol,2009,157(2):310-315.
[28] Dong X,Li X,Li M,et al.Antiinflammation and antioxidant effects of thalidomide on pulmonary fibrosis in mice and human lung fibroblasts[J].Inflammation,2017,40(6):1836-1846.
[29] 刘涛,谢媛,徐梦桐,等.沙利度胺对百草枯中毒ALI大鼠的保护作用及机制[J].中华危重病急救医学,2017,29(11):981.
[30] Amirshahrokhi K.Anti-inflammatory effect of thalidomide in paraquat-induced pulmonary injury in mice[J].Int Immunopharmacol,2013,17(2):210-215.
[31] Tabata C,Tabata R,Takahashi Y,et al.Thalidomide prevents cigarette smoke extract-induced lung damage in mice[J].Int Immunopharmacol,2015,25(2):511-517.
[32] Wen H,Ma H,Cai Q,et al.Recurrent ECSIT mutation encoding V140A triggers hyperinflammation and promotes hemophagocytic syndrome in extranodal NK/T cell lymphoma[J].Nat Med,2018,24(2):154-164.
[33] Majumder S,Sreedhara SR,Banerjee S,et al.TNF α signaling beholds thalidomide saga:a review of mechanistic role of TNF-α signaling under thalidomide[J].Curr Top Med Chem,2012,12(13):1456-1467.
[34] Kwon HY,Han YJ,Im JH,et al.Two cases of immune reconstitution inflammatory syndrome in HIV patients treated with thalidomide[J].Int J STD AIDS,2019,30(11):1131-1135.
[35] Reid E,Suneja G,Ambinder R,et al.AIDS-related Kaposi sarcoma,Version 2.2019,NCCN clinical practice guidelines in oncology[J].J Natl Compr Canc Netw,2019,17(2):171-189.
[36] Jacobson JM,Greenspan JS,Spritzler J,et al.Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection[J].N Engl J Med,1997,336(21):1487-1493.
[37] Ba H,Xu L,Peng H,et al.Chronic active epstein-barr virus infection with systemic vasculitis and pulmonary arterial hypertension in a child[J].Front Pediatr,2019,7:219.
[38] Xu L,Ba H,Lin H,et al.A new therapy in Epstein-Barr virus-associated lymphoproliferative disease:a case report and a revision of the literature[J].Ital J Pediatr,2019,45(1):135.
[39] 张小凡,丁家祥,薛江洲,等.沙利度胺治疗慢性乙型肝炎的初步研究[J].临床肝胆病杂志,2005,21(3):153-155.
[40] 邢晓燕,鞠贞会,孙书乾.沙利度胺联用抗风湿药物对合并慢性乙型肝炎的类风湿关节炎疗效的观察[J].中国医药指南,2012,10(7):205-207.
[41] 刘涛,袁睿,刘林,等.沙利度胺与环磷酰胺治疗百草枯中毒致肝肾损伤效果评价[J].中国卫生标准管理,2017,8(3):70-72.
[42] 中国医师协会皮肤科分会变态反应性疾病专业委员会.慢性瘙痒管理指南(2018版)[J].中华皮肤科杂志,2018,51(7):481-485.
[43] 王宏伟,张洁尘.老年皮肤瘙痒症诊断与治疗专家共识[J].中国皮肤性病学杂志,2018,32(11):9-13.
[44] Weisshaar E,Szepietowski JC,Dalgard FJ,et al.European S2k guideline on chronic pruritus[J].Acta Derm Venereol,2019,99(5):469-506.
[45] Soleymanian T,Soleimani A,Musavi A,et al.Outcome of patients with multiple myeloma and renal failure on novel regimens[J].Saudi J Kidney Dis Transpl,2016,27(2):335-340.
[46] 多发性骨髓瘤肾损伤诊治专家共识协作组.多发性骨髓瘤肾损伤诊治专家共识[J].中华内科杂志,2017,56(11):871-875.
[47] Chen TL,Vogelsang GB,Petty BG,et al.Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers[J].Drug Metab Dispos,1988,17(4):402-405.
[48] Swigris JJ,Brown KK,Belkin A.Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis[J].Ann Intern Med,2013,158(6):498.
[49] Molassiotis A,Smith JA,Mazzone P,et al.Symptomatic treatment of cough among adult patients with lung cancer:CHEST guideline and expert panel report[J].Chest,2017,151(4):861-874.
[50] Govindarajan R,Heaton KM,Broadwater R,et al.Effect of thalidomide on gastrointestinal toxic effects of irinotecan[J].Lancet,2000,356(9229):566-567.
[51] Gerich ME,Yoon JL,Targan SR,et al.Long-term outcomes of thalidomide in refractory Crohn's disease[J].Aliment Pharmacol Ther,2015,41(5):429-437.
[52] 姜文奇,巴一,冯继锋,等.肿瘤药物治疗相关恶心呕吐防治中国专家共识(2019年版)[J].中国医学前沿杂志,2019,11(11):16-26.
[53] Hatemi G,Christensen R,Bang D,et al.2018 update of the EULAR recommendations for the management of Behçet's syndrome[J].Ann Rheum Dis,2018,77(6):808-818.
[54] 中华医学会消化病学分会炎症性肠病学组.炎症性肠病诊断与治疗的共识意见(2012年·广州)[J].中华内科杂志,2012,51(10):818-831.
[55] 中华医学会消化病学分会炎症性肠病学组.炎症性肠病诊断与治疗的共识意见(2018年·北京)[J].中华消化杂志,2018,38(5):131-292.
[56] Schwartz DA,Ghazi LJ,Regueiro M.Guidelines for medical treatment of Crohn's perianal fistulas:critical evaluation of therapeutic trials[J].Inflamm Bowel Dis,2015,21(4):737-752.
[57] Rostamian A,Gharedaghi A,Norouzi-Javidan A,et al.Involvement of the nitric oxide pathway in the anti-depressant-like effects of thalidomide in mice[J].Physiol Behav,2019,208:112572.
[58] 谌介秀,李宁,颜芳,等.沙利度胺改善伊立替康围化疗期睡眠障碍的临床观察[J].中国药师,2019,22(1):98-100.
[59] Peltier AC,Russell JW.Advances in understanding drug-induced neuropathies[J].Drug Saf,2006,29(1):23-30.
[60] Sharma D,Kwatra SG.Thalidomide for the treatment of chronic refractory pruritus[J].J Am Acad Dermatol,2016,74(2):363-369.
[61] Kato A,Takano H,Ichikawa A,et al.A retrospective cohort study of venous thromboembolism(VTE)in 1035 Japanese myeloma patients treated with thalidomide; lower incidence without statistically significant association between specific risk factors and development of VTE and effects of thromboprophylaxis with aspirin and warfarin[J].Thromb Res,2013,131(2):140-144.
[62] Yin QS,Chen L,Mi RH,et al.Efficacy and safety of danshen compound tablets in preventing thalidomide-associated thromboembolism in patients with multiple myeloma:a multicenter retrospective study[J].Med Sci Monit,2016,22:3835-3842.

备注/Memo

备注/Memo:
[通信作者] 郑捷,E-mail:jie-zheng2001@126.com
[Corresponding author]ZHENG Jie,E-mail:jie-zheng2001@126.com
[网络首发时间] 2020-3-11 17:07
[网络首发地址] http://kns.cnki.net/kcms/detail/61.1197.R.20200311.1616.001.html
更新日期/Last Update: 2020-06-05